Weazel,
News like this SHOULD move the stock price.
This is news of significance but the message again is destroyed by its content. Period.
Having the potential for a treatment for mycoplasma bovis (pathogen the causes pneumonia, mastitis, arthritis ... among others) is where the $$$$ are. Anyone can google mycoplasma bovis and find there are only methods described on how to possibly manage or control the pathogen rather than an actual treatment for it.
NOBODY HAS AN APPROVED TREATMENT FOR IT. Closest is an antibiotic therapy that may or may not do anything.
Also, the study was done on dairy cattle so I get why only dairy cattle was mentioned, however mycoplasma bovis is possible in ALL types of cattle. So application potential is not just the worldwide civilized dairy herd but ALL cattle as well.
The downside of dealing with a Zoetis is they are slow as molasses and controlling. Since ZIVO is in exclusive agreement with Zoetis, I'm 100% certain Zoetis fingerprints all over that PR. They aren't going to allow anything to be offered they don't want to have known. Problem is investors need to know more. No question in my mind that if ZIVO was doing this on their own that we would have more information and several of the top 10 animal health companies would have interest. That competitive interest makes all the difference in the world in getting movement from the big boys ....... unfortunately we don't have the competition here.
What do investors need to know ?? Is the study data on record as of this study sufficient to talk license with Zoetis ?? Does it fulfill the requirement outlined in the initial exclusive agreement ??? That is what it boils down too. Unfortunately there is no information offered on it.
We have Dahl on Red Chip TV saying license potentially within months.
Soooooooooo ..... investors haven't a clue where the company is based on the information available and this PR. That is the reason the stock did not move. Not enough information from ZIVO.
"In a parallel development, The Company is exploring several near-term applications, where the original natural biomass is minimally processed, relying primarily on its signature lipids and peptides to offer a natural nutritive profile. In so doing, management is opening talks with potential production partners." We've been hearing about a minimally processed biomass option for some time and it would be the nearest term monetization option. Soooooooo ...........
Amigo Mike
